SLC5A2 and heart failure: Suffice it to say, it is reasonable to consider newer or alternative heart failure medications in children with chronic graft dysfunction who have refractory symptoms, intolerance to other anti-congestive therapies, or where benefit may be derived from other effects of the treatment such as the potential for SGLT2 inhibitors to improve serum glucose.